Wafermine

The company says the study unlocks Wafermine’s potential to address the global cancer pain market, estimated at US$5.5 bil.

The biotech company could finally turn profitable in FY21 as revenue could be bumped up by as much as 250%, says the brokerage.

SINGAPORE (Oct 13): DBS Group Research has derived a fair value estimate of 43 cents for iX Biopharma in its preliminary assessment of what it deems a high-risk stock, with a view that investors should expect 0-20% potential returns from the stock over th

SINGAPORE (Aug 26): iX Biopharma is a small Catalist-listed Singapore company focusing on a big goal: Developing pain management drugs that are an alternative to opioids, and the optimum system to deliver these drugs into the body.

SINGAPORE (Aug 25): iX Biopharma reported net losses of $7.7 million for FY16, a 25% improvement over the net losses of $10.4 million in FY15.